Frontier Biotechnology
- Biotech or pharma, therapeutic R&D
Frontier Biotechnologies Inc. is a research-based, commercial-stage, publicly-traded biopharma company dedicated in the discovery, development, manufacture and commercialization of innovative medicines. We are a 20-year young and ~300-people strong company founded by a group of US-trained scientists, had our first product approval in China in 2018, and went public on Shanghai Stock Exchange in 2020. We have discovered and developed China’s first new anti-HIV drug called Aikening, aka Albuvirtide, which is also the first long-acting injectable HIV fusion inhibitor in the world.
We have built a science-based commercial team to promote Aikening in China and 5 emerging markets, with broad coverage of hospitals and DTP pharmacies, track record in strong sales growth and getting Aikening into Chinese National Reimbursement Drug List and Guidelines.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}